Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980627 · ClinicalTrials.gov registry record · NA
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT02980627 is a NA study that has completed, run by Duke University. The registered enrollment target is 27 participants.
The verdict
NCT02980627, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Individuals with type 1 diabetes who intentionally omit insulin to lose weight are at high risk for diabetes-related medical complications and premature death. Conventional eating disorder (ED) treatments are not as effective for these patients, suggesting that they need a more tailored treatment approach and one that includes intervention at the time and place when they are making decisions about their diabetes self-management. The goal of treatment development project is to modify an existing mobile application (app) for EDs (Recovery Record; RR) to address the unique needs of adults with type 1 diabetes (T1D) who intentionally omit their insulin for weight control, and test whether app-supported individual treatment decreases eating disorder (ED) symptoms and improves metabolic control. The investigator will also gather preliminary data on the impact of the intervention on health care utilization and costs and calculate attrition to assess feasibility. The investigators hypothesize that (1) participants will evidence significant decreases in mean blood glucose, (2) participation in routine medical care will increase and emergency visits will decrease, (3) the percentage of time participants are hyperglycemic will decrease, (4) participant scores on the DEPS-R will decrease and (5) participant scores on the EDE will decrease.
Interventions
- BEHAVIORAL Therapy with Mobile App Enhancement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-05-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02980627
The ClinicalTrials.gov registry entry for NCT02980627 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Therapy with Mobile App Enhancement is the first listed.
NCT02980627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02980627 about?
NCT02980627 is a clinical study titled "iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes". Individuals with type 1 diabetes who intentionally omit insulin to lose weight are at high risk for diabetes-related medical complications and premature death. Conventional eating disorder (ED) treatments are not as effective for these patients, suggesting that they need a more tailored treatment ap...
What is the current status of trial NCT02980627?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2016-03. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT02980627?
The interventions under investigation include: Therapy with Mobile App Enhancement (BEHAVIORAL).
Who is sponsoring clinical trial NCT02980627?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.